Claus Werenberg Marcher

Author

Also Known As

C Marcher, C W Marcher, C. W. Marcher, Carolin Marcher, Claus Marcher, Claus W. Marcher, Claus Werenberg Marcher, M Severinsen, Marcher, Claus W

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Odense University Hospital Rigshospitalet Aarhus University Hospital Herlev Hospital Copenhagen University Hospital

About

Claus Werenberg Marcher is an author at Odense University Hospital specializing in medicine, hematology, and outcomes research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	934
2	Health Sciences	3	3	621
3	Public Health	3	3	141
4	Health Policy	3	3	141
5	Epidemiology	2	2	101

Claus Werenberg Marcher

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study Gregory Cheng, Mansoor N. Saleh, Claus Werenberg Marcher, The Lancet ThrombopoiesisThrombosisVenous ThrombosisAutoimmune DiseaseBlood Platelet	2010	574
Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study Lene Sofie Granfeldt Østgård, Bruno C. Medeiros, Henrik Sengeløv, Journal of Clinical Oncology	2015	436
Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha Thomas Stauffer Larsen, Katrine Fladeland Iversen, Esben Hansen, Leukemia Research InflammationThrombosisPolycythemia VeraThrombopoiesisHematological Malignancy	2013	90
Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission Thomas Stauffer Larsen, Michael Møller, Karin de Stricker, Hematology Hematological MalignancyPolycythemia VeraBone Marrow FailureAutoimmune DiseaseMalignant Blood Disorder	2009	82
Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study Lene Sofie Granfeldt Østgård, Jan Maxwell Nørgaard, Henrik Sengeløv, Leukemia Hematological MalignancyHealth PolicyMixed-phenotype Acute LeukemiaHematologyMyeloid Neoplasia	2014	76
Extramedullary disease in patients with acute myeloid leukemia assessed by (18)F‐<scp>FDG PET</scp> Anne‐Sofie Weindel Ibar Cribe, Maria Steenhof, Claus Werenberg Marcher, European Journal Of Haematology	2013	60
Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial Magnus Tobiasson, I Dybedahl, Mette Skov Holm, Blood Cancer Journal	2014	55
Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort Study Lene Sofie Granfeldt Østgård, Mette Nørgaard, Bruno C. Medeiros, Journal of Clinical Oncology Mixed-phenotype Acute LeukemiaEpidemiology Of CancerHealth DisparitiesCox RegressionCancer Disparity	2017	36
Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE) Gregory Cheng, Mansoor N. Saleh, James B. Bussel, Blood	2008	35
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman, Journal of Clinical Oncology	2024	31

Page 1